Riccardo Magistroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3984890/publications.pdf

Version: 2024-02-01

73 papers	5,720 citations	172207 29 h-index	114278 63 g-index
83 all docs	83 docs citations	83 times ranked	6378 citing authors

#	Article	IF	Citations
1	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2012, 367, 2407-2418.	13.9	1,267
2	Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 205-212.	3.0	590
3	Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature Genetics, 2011, 43, 321-327.	9.4	528
4	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	9.4	505
5	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International, 2014, 86, 828-836.	2.6	373
6	New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney International, 2015, 88, 974-989.	2.6	211
7	The MEST score provides earlier risk prediction in lgA nephropathy. Kidney International, 2016, 89, 167-175.	2.6	190
8	Corticosteroids in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2248-2258.	3.0	187
9	Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1164-1174.	3.0	129
10	Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1394-1400.	2.2	123
11	Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36. Journal of the American Society of Nephrology: JASN, 2007, 18, 2408-2415.	3.0	112
12	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 972-982.	3.0	103
13	Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. Journal of Proteomics, 2011, 74, 2008-2017.	1.2	101
14	Progressive Loss of Renal Function Is an Age-Dependent Heritable Trait in Type 1 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 755-762.	3.0	84
15	Urine Proteome Analysis May Allow Noninvasive Differential Diagnosis of Diabetic Nephropathy. Diabetes Care, 2010, 33, 2409-2415.	4.3	83
16	COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. American Journal of Transplantation, 2020, 20, 1902-1906.	2.6	81
17	Hypokalemia in Patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 401-409.	0.7	78
18	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron, 2016, 132, 15-24.	0.9	60

#	Article	IF	Citations
19	Genetic Variation of DKK3 May Modify Renal Disease Severity in ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1510-1520.	3.0	59
20	The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE, 2018, 13, e0190430.	1.1	57
21	Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney International, 2003, 64, 149-159.	2.6	56
22	Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study. American Journal of Kidney Diseases, 2010, 56, 506-512.	2.1	53
23	A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression. American Journal of Nephrology, 2018, 48, 67-78.	1.4	51
24	Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients WithÂCOVID-19. Kidney International Reports, 2020, 5, 1815-1822.	0.4	45
25	Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Nephrology Dialysis Transplantation, 2006, 21, 3155-3163.	0.4	35
26	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney International, 2020, 98, 1009-1019.	2.6	35
27	Evaluation of the Classification Accuracy of the Kidney Biopsy Direct Immunofluorescence through Convolutional Neural Networks. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1445-1454.	2.2	34
28	Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	32
29	Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin. Nephrology Dialysis Transplantation, 2009, 24, 1672-1681.	0.4	30
30	Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Scientific Reports, 2016, 6, 30850.	1.6	28
31	Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans. Journal of Nephrology, 2017, 30, 511-519.	0.9	28
32	Incidence, risk factors and outcome of acute kidney injuryÂ(AKI) in patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 1203-1214.	0.7	27
33	Acid base disorders in patients with COVID-19. International Urology and Nephrology, 2022, 54, 405-410.	0.6	26
34	The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review. Journal of Nephrology, 2021, 34, 1387-1403.	0.9	24
35	Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?. Journal of Nephrology, 2015, 28, 51-58.	0.9	23
36	Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. CKJ: Clinical Kidney Journal, 2020, 13, 334-339.	1.4	19

#	Article	IF	Citations
37	The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection. Blood Purification, 2021, 50, 263-267.	0.9	17
38	ADPKD current management and ongoing trials. Journal of Nephrology, 2020, 33, 223-237.	0.9	16
39	OUP accepted manuscript. CKJ: Clinical Kidney Journal, 2020, 13, 265-268.	1.4	16
40	Identification and Characterization of a New Autoimmune Protein in Membranous Nephropathy by Immunoscreening of a Renal cDNA Library. PLoS ONE, 2012, 7, e48845.	1.1	14
41	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. Kidney Research and Clinical Practice, 2021, 40, 231-240.	0.9	14
42	A pilot study to evaluate tolerability and safety of a modified Atkins diet in ADPKD patients. PharmaNutrition, 2019, 9, 100154.	0.8	13
43	Lipoprotein Glomerulopathy Associated with a Mutation in Apolipoprotein E. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12209.	0.3	12
44	Reliability of Total Renal Volume Computation in Polycystic Kidney Disease From Magnetic Resonance Imaging. Academic Radiology, 2015, 22, 1376-1384.	1.3	12
45	Comparison of Total Kidney Volume Quantification Methods in Autosomal Dominant Polycystic Disease for a Comprehensive Disease Assessment. American Journal of Nephrology, 2017, 45, 373-379.	1.4	12
46	TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes. BMC Nephrology, 2019, 20, 355.	0.8	12
47	Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open, 2019, 9, e029232.	0.8	11
48	GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients. PharmaNutrition, 2020, 13, 100206.	0.8	10
49	Longâ€term effects of COVID â€19 in a patient on maintenance dialysis. Hemodialysis International, 2020, 24, E50-E54.	0.4	9
50	Oneâ€year persistence of neutralizing <scp>antiâ€</scp>SARSâ€CoVâ€2 antibodies in dialysis patients recovered from COVIDâ€19. Hemodialysis International, 2021, 25, E53-E56.	0.4	8
51	Clinical Predictors of Nondiabetic Kidney Disease in Patients with Diabetes: A Single-Center Study. International Journal of Nephrology, 2021, 2021, 1-7.	0.7	7
52	A validated model of disease progression in IgA nephropathy. Journal of Nephrology, 2006, 19, 32-40.	0.9	7
53	Artificial intelligence in glomerular diseases. Pediatric Nephrology, 2022, 37, 2533-2545.	0.9	7
54	Confidence Calibration for Deep Renal Biopsy Immunofluorescence Image Classification. , 2021, , .		5

#	Article	IF	Citations
55	Interstitial fluid obtained from kidney biopsy as new source of renal biomarkers. Journal of Nephrology, 2011, 24, 329-337.	0.9	4
56	Seroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants. CKJ: Clinical Kidney Journal, 2021, 14, 1983-1984.	1.4	4
57	Acid base disorders in patients with COVID-19. International Urology and Nephrology, 2021, , .	0.6	4
58	Ethical challenges in managing unvaccinated patients receiving chronic in-centre haemodialysis. CKJ: Clinical Kidney Journal, 2022, 15, 615-617.	1.4	4
59	Which criteria should we use to end isolation in hemodialysis patients with COVID-19?. CKJ: Clinical Kidney Journal, 0, , .	1.4	3
60	Comment on the Paper: Â‘Novel Approach to Estimate Kidney and Cyst Volumes Using Mid-Slice Magnetic Resonance Images in Polycystic Kidney Disease'. American Journal of Nephrology, 2014, 39, 163-164.	1.4	2
61	Geometry-independent assessment of renal volume in polycystic kidney disease from magnetic resonance imaging. , 2015, 2015, 3081-4.		2
62	Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease. Giornale De Techniche Nefrologiche & Dialitiche, 2017, 29, 80-84.	0.1	2
63	Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease. International Journal of Nephrology, 2021, 2021, 1-9.	0.7	2
64	Response letter to the Editorial: "Ketogenic diet in ADPKD patients". PharmaNutrition, 2021, 16, 100268.	0.8	2
65	Epidermal growth factor receptor polymorphism and autosomal dominant polycystic kidney disease. Journal of Nephrology, 2003, 16, 110-5.	0.9	2
66	Hybrid dialysis: a promising strategy to reduce hospital access during the SARS-CoV-2 pandemic. BMJ Case Reports, 2020, 13, e236411.	0.2	1
67	Methicillin-Resistant Staphylococcus aureus Peritonitis due to Hematogenous Dissemination from Central Venous Catheter in a Maintenance Dialysis Patient. Case Reports in Nephrology and Dialysis, 2021, 11, 281-285.	0.3	1
68	Monoclonal B lymphocytosis in a kidney transplant recipient. BMJ Case Reports, 2021, 14, e242889.	0.2	0
69	Advances in Genetics of Immunoglobulin A Nephropathy. , 2016, , 19-42.		0
70	AKI in hospitalized patients with COVID-19: a single-center experience. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2021, 38, .	0.3	0
71	Immunosuppressive therapy reduction and early post-infection graft function in kidney transplant recipients with COVID-19.. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2021, 38, .	0.3	0
72	Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective study.. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2022, 39, .	0.3	0

#	Article	IF	Citations
73	MO137: Sarcoidosis in a Living Kidney Donor Candidate: Case Report and Review of the Literature. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0